Bernhard J Eigl
Overview
Explore the profile of Bernhard J Eigl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
3193
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calvo E, Doger B, Carles J, Peer A, Sarid D, Eigl B, et al.
Oncologist
. 2025 Jan;
30(1).
PMID: 39832129
Background: Metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis, necessitating the investigation of novel treatments and targets. This study evaluated JNJ-70218902 (JNJ-902), a T-cell redirector targeting transmembrane protein with...
2.
Powles T, Catto J, Galsky M, Al-Ahmadie H, Meeks J, Nishiyama H, et al.
N Engl J Med
. 2024 Sep;
391(19):1773-1786.
PMID: 39282910
Background: Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve outcomes. Methods: In this phase 3, open-label,...
3.
Fonseca N, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha A, et al.
Nat Commun
. 2024 Feb;
15(1):1828.
PMID: 38418825
No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratification...
4.
Moria F, Park C, Eigl B, Macfarlane R, Pavic M, Saleh R
Curr Oncol
. 2024 Feb;
31(2):704-722.
PMID: 38392046
Locally advanced or metastatic urothelial carcinoma (aUC) presents a significant challenge with high mortality rates. Platinum-based chemotherapy remains the established frontline standard of care, and a switch-maintenance strategy with immunotherapy...
5.
6.
Petrylak D, Eigl B, George S, Heath E, Hotte S, Chism D, et al.
Clin Cancer Res
. 2023 Oct;
30(1):63-73.
PMID: 37861407
Purpose: Effective treatment of locally advanced or metastatic urothelial carcinoma (mUC) remains an unmet need. Antibody-drug conjugates (ADC) providing targeted drug delivery have shown antitumor activity in this setting. AGS15E...
7.
Fleshner N, Alibhai S, Connelly K, Martins I, Eigl B, Lukka H, et al.
Ther Adv Med Oncol
. 2023 Apr;
15:17588359231152845.
PMID: 37007631
Background: Orally administrated agents play a key role in the management of prostate cancer, providing a convenient and cost-effective treatment option for patients. However, they are also associated with adherence...
8.
Benard F, Harsini S, Wilson D, Zukotynski K, Abikhzer G, Turcotte E, et al.
Lancet Oncol
. 2022 Nov;
23(12):1499-1507.
PMID: 36343655
Background: Detection of skeletal metastases in patients with prostate cancer or breast cancer remains a major clinical challenge. We aimed to compare the diagnostic performance of Tc-methylene diphosphonate (Tc-MDP) single-photon...
9.
Lavoie J, Baichoo P, Chavez E, Nappi L, Khalaf D, Kollmannsberger C, et al.
Front Oncol
. 2022 Sep;
12:973402.
PMID: 36176410
Immune checkpoint inhibitors (ICI) are used in the treatment of urothelial and renal cell cancers. While some patients may have exceptional responses, better predictive biomarkers are needed. We profiled the...
10.
Sundquist S, Batist G, Brodeur-Robb K, Dyck K, Eigl B, Lee D, et al.
Curr Oncol
. 2021 Oct;
28(5):3857-3865.
PMID: 34677247
Canada's vast geography, and centralized delivery of cancer care and clinical trials create barriers for trial participation for patients in remote and rural settings. The development and implementation of a...